0 CHECKOUT

Pruritus - Pipeline Review, H1 2015

  • ID: 3150113
  • February 2015
  • 91 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AlbireoPharma
  • Cara Therapeutics, Inc.
  • Creabilis SA
  • FAES Farma SA
  • Helsinn Holding S.A.
  • LEO Pharma A/S
  • MORE

Pruritus - Pipeline Review, H1 2015

Summary

This, ‘Pruritus - Pipeline Review, H1 2015’, provides an overview of the Pruritus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlbireoPharma
  • Cara Therapeutics, Inc.
  • Creabilis SA
  • FAES Farma SA
  • Helsinn Holding S.A.
  • LEO Pharma A/S
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pruritus Overview
Therapeutics Development
Pipeline Products for Pruritus - Overview
Pipeline Products for Pruritus - Comparative Analysis
Pruritus - Therapeutics under Development by Companies
Pruritus - Therapeutics under Investigation by Universities/Institutes
Pruritus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pruritus - Products under Development by Companies
Pruritus - Products under Investigation by Universities/Institutes
Pruritus - Companies Involved in Therapeutics Development
AlbireoPharma
Amorepacific Corporation
Cara Therapeutics, Inc.
Conrig Pharma ApS
Creabilis SA
ELORAC, Inc.
FAES Farma SA
GlaxoSmithKline plc
Helsinn Holding S.A.
Hydra Biosciences, Inc.
LEO Pharma A/S
Merck & Co., Inc.
NeRRe Therapeutics Ltd
Nippon Shinyaku Co., Ltd.
RDD Pharma Ltd.
Shionogi & Co., Ltd.
Tioga Pharmaceuticals, Inc.
Trevi Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Pruritus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASN-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bilastine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-746 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-845 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRG-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-327 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
desloratadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
netupitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Pruritus Ani - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize CB2 for Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pruritus - Recent Pipeline Updates
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pruritus, H1 2015
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Pruritus - Pipeline by AlbireoPharma, H1 2015
Pruritus - Pipeline by Amorepacific Corporation, H1 2015
Pruritus - Pipeline by Cara Therapeutics, Inc., H1 2015
Pruritus - Pipeline by Conrig Pharma ApS, H1 2015
Pruritus - Pipeline by Creabilis SA, H1 2015
Pruritus - Pipeline by ELORAC, Inc., H1 2015
Pruritus - Pipeline by FAES Farma SA, H1 2015
Pruritus - Pipeline by GlaxoSmithKline plc, H1 2015
Pruritus - Pipeline by Helsinn Holding S.A., H1 2015
Pruritus - Pipeline by Hydra Biosciences, Inc., H1 2015
Pruritus - Pipeline by LEO Pharma A/S, H1 2015
Pruritus - Pipeline by Merck & Co., Inc., H1 2015
Pruritus - Pipeline by NeRRe Therapeutics Ltd, H1 2015
Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015
Pruritus - Pipeline by RDD Pharma Ltd., H1 2015
Pruritus - Pipeline by Shionogi & Co., Ltd., H1 2015
Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H1 2015
Pruritus - Pipeline by Trevi Therapeutics, Inc., H1 2015
Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pruritus Therapeutics - Recent Pipeline Updates, H1 2015
Pruritus - Dormant Projects, H1 2015
Pruritus - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Pruritus, H1 2015
Number of Products under Development for Pruritus - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- AlbireoPharma
- Amorepacific Corporation
- Cara Therapeutics, Inc.
- Conrig Pharma ApS
- Creabilis SA
- ELORAC, Inc.
- FAES Farma SA
- GlaxoSmithKline plc
- Helsinn Holding S.A.
- Hydra Biosciences, Inc.
- LEO Pharma A/S
- Merck & Co., Inc.
- NeRRe Therapeutics Ltd
- Nippon Shinyaku Co., Ltd.
- RDD Pharma Ltd.
- Shionogi & Co., Ltd.
- Tioga Pharmaceuticals, Inc.
- Trevi Therapeutics, Inc.
- Vanda Pharmaceuticals Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare